Innovate UK Biomedical Catalyst Accelerator - Future Medicines
Published on 03/09/2025
Bionow is pleased to be a programme partner for the Innovate UK Biomedical Catalyst Accelerator - Future Medicines, a national programme supporting UK innovators to develop the next generation of medical treatments and technologies. It is designed for early-stage companies (TRL2-4) working on transformative innovations in future medicines, with radiopharmaceuticals identified as a priority area.
Participants will gain access to:
Participants will gain access to:
- World-leading expertise in drug discovery, development, and regulation
- Market research, competitive analysis, and commercial strategy support
- Investment readiness training, pitch preparation, and funding guidance
- Access to cutting-edge research facilities and networking with sector experts
- The opportunity to work with partners to develop fully funded technical roadmaps
- Face-to-face peer and investor events
Programme Structure
Pre-Accelerator (Nov 2025 - Dec 2025):
Companies will build a strong foundation in drug discovery, development, regulation, market strategy, and exploitation planning, with guidance on grants, early-stage financing, and investment readiness - while establishing a peer-to-peer network.
Accelerator (Jan 2026 - Mar 2026):
A select group from this cohort will receive tailored technical, scientific, and commercial support, a detailed R&D and exploitation plan, investor pitch training, sector-specific introductions, and a personalised pack to support future funding.
Eligibility
The Future Medicines Accelerator is open to:
- UK-registered SMEs (or academics in the early stages of forming an SME)
- Companies developing a novel product, technology, process, or service addressing a clear healthcare challenge
- Early-stage development (TRL2–4)
- Alignment with future medicines scope*, with radiopharmaceuticals as a priority area, microbiome-based therapies, biopharmaceuticals, regenerative and personalised medicines, and gene therapies
- Clear benefit from participating in the programme
*Out of scope: Development of long-acting therapeutics
Application Details
Applications close: 12pm on 26th September 2025
Please direct any business enquiries or requests for further information to: futuremedicines.accelerator@lyvalabs.com
Application web page: https://lyvalabs.com/future-medicines
Application link: https://lyvalabs.com/future-medicines-apply
Programme Leaders
LYVA Labs • Innovate UK
Programme Partners
Bionow • Medicines Discovery Catapult (MDC) • Cell & Gene Therapy Catapult (CGT) • Microbiome Innovation Centre (MIC) • Infection Innovation Consortium (iiCON) • Future Medicines Institute (FMI) • Centre for Process Innovation (CPI) • UK National Nuclear Laboratory (UKNNL)
Application Details
Applications close: 12pm on 26th September 2025
Please direct any business enquiries or requests for further information to: futuremedicines.accelerator@lyvalabs.com
Application web page: https://lyvalabs.com/future-medicines
Application link: https://lyvalabs.com/future-medicines-apply
Programme Leaders
LYVA Labs • Innovate UK
Programme Partners
Bionow • Medicines Discovery Catapult (MDC) • Cell & Gene Therapy Catapult (CGT) • Microbiome Innovation Centre (MIC) • Infection Innovation Consortium (iiCON) • Future Medicines Institute (FMI) • Centre for Process Innovation (CPI) • UK National Nuclear Laboratory (UKNNL)
